"Thiosemicarbazones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D013882
|
| MeSH Number(s) |
D02.845.746.703 D02.886.803
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thiosemicarbazones".
Below are MeSH descriptors whose meaning is more specific than "Thiosemicarbazones".
This graph shows the total number of publications written about "Thiosemicarbazones" by people in this website by year, and whether "Thiosemicarbazones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 1 | 2 |
| 2010 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thiosemicarbazones" by people in Profiles.
-
E. coli Ribonucleotide Reductase ?2 Subunit Inactivation by Triapine Occurs through Binding of a Triapine-Fe(II) Adduct. J Phys Chem Lett. 2021 Sep 23; 12(37):9020-9025.
-
COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms. Clin Cancer Res. 2019 09 15; 25(18):5650-5662.
-
Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine?) in cancer patients. Cancer Chemother Pharmacol. 2011 Feb; 67(2):393-400.
-
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. Cancer Chemother Pharmacol. 2010 Oct; 66(5):973-80.
-
A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2009 May; 63(6):1147-56.
-
Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors. Cancer Chemother Pharmacol. 2009 Jun; 64(1):79-86.
-
Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine. J Inorg Biochem. 2008 Apr; 102(4):693-8.
-
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk Res. 2006 Jul; 30(7):813-22.
-
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res. 2003 Dec; 27(12):1077-83.
-
Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Lett. 2002 May 28; 179(2):141-50.